Skip to main content
Close Search
HIRO LogoHIRO Logo WhiteHiro Logo Blue
Menu
  • About Us
  • Service Modes
    • Functional Service Provider
    • Clinical Data Science
    • Clinical Operations
    • Medical Monitoring
    • Pharmacovigilance
    • Quality Assurance
    • Regulatory Affairs
    • Medical Writing
  • Therapeutic Expertise
    • Oncology
    • Rare Diseases
    • Healthy Volunteers
    • Dermatology
    • Metabolic
  • Modalities
    • Radiopharmaceutical
    • Cell and Gene Therapy
  • Regions
    • U.S.
    • APAC
    • ANZ
    • Europe
  • Updates
    • Events and News
    • Blogs
    • Case Studies
    • View All
  • Contact
  • Start Your RFP

    Taiwan & Hong Kong: Strategic Hubs for Global Development

    By Vicky HuiBlogs
    No Comments

    The APAC region continues to play a critical role in the global landscape of drug development, with a strong focus on optimizing clinical trials.

    While smaller markets, Taiwan and Hong Kong, may not be as prominent as some larger APAC countries/regions, both are making significant efforts to enhance clinical trial efficiency in order for studies to maximize the opportunities these regions present.

    In order to make the most out of what Taiwan and Hong Kong have to offer, it’s important to understand their unique trial landscapes, regulatory environments, and key strategies that can drive success in global drug development.

     

    Taiwan Overview

     

    The demographic landscape of Taiwan presents a good recruitment opportunity for clinical researchers. With an aging population, Taiwan offers access to a diverse patient pool across various therapeutic areas.

    Leading causes of death in Taiwan include [1]:

    • Malignant neoplasms
    • Heart disease
    • Pneumonia
    • Cerebrovascular diseases
    • Diabetes Mellitus

     

    Taiwan’s market growth is supported by a regulatory environment that actively facilitates efficient clinical trial execution, offering streamlined processes that enable quick study startups and streamlined trial operations.

    Taiwan also includes more than 100 hospitals and medical institutions that are actively involved in clinical trials [1]. There are also:

    • More than 2,000 qualified Principal Investigators
    • 9 main Institutional Review Boards (IRBs) and 35 sub-review IRBs accredited for clinical trial oversight
    • 12 organizations accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP)
    • 24 Ethics Committees/IRBs recognized by SIDCER-FERCAP (Strategic Initiative for Developing Capacity in Ethical Review – Forum for Ethical Review Committees in the Asian and Western Pacific Region)

     

    Taiwan’s Healthcare Infrastructure

     

    Most medical centers in Taiwan have adopted Electronic Medical Record (EMR) systems, which allow efficient medical recording and data tracking. This digital system helps physicians maintain accurate patient histories and monitor ongoing treatments.

    Taiwan’s National Health Insurance (NHI) covers nearly 100% of the population. Through this universal healthcare system, physicians can see a complete picture of patient visits and medical history, which helps them provide better evaluations and treatment decisions.

    In 2014, Taiwan launched the My Health Bank system, where patients can search for available trials and related information. This initiative aims to improve patient access to clinical research opportunities and enhance trial participation.

     

    Taiwan’s Clinical Trial Landscape

     

    Clinical trials in Taiwan span a diverse range of therapeutic areas, including [2]:

    • Oncology
    • Heart disease
    • Respiratory diseases

     

    In 2013, Taiwan’s Centers for Disease Control (CDC) set up the Central IRB (c-IRB) mechanism to improve the review process for multi-center clinical trials. Under this system, when a multicenter trial is registered, at least one site is assigned as the main c-IRB reviewer to conduct a full-board review. The main IRB completes their review within 20 working days, and then other sub-IRBs complete their reviews within 10 days. For US FDA-approved trials, the approval process may be even faster.

     

    Taiwan’s Regulatory Framework and Timelines

     

    Taiwan offers significant advantages through its Certificate of Pharmaceutical Product (CPP) waiver program. Companies incorporating Taiwan in their global clinical trials may be eligible to waive one or both CPP requirements for future marketing authorization applications.

    The regulatory framework includes expedited IND pathways that accelerate the approval process. For example, Fast Track review is available for studies conducted in both the US and Taiwan, and Clinical Trial Notification (CTN) review is available for multi-center trials that involve at least one medical center in Taiwan, provided the trial uses the same approved IND protocol and is conducted simultaneously in one of 10 recognized countries, which include Germany, US, UK, France, Japan, Switzerland, Canada, Australia, Belgium, and Sweden.

    Timeline and Process Efficiency

    The timeline from protocol to first site initiation visit typically spans around five months, with several parallel processes enhancing efficiency:

    • Document preparation usually requires one month, though this may extend if multiple informed consent forms or additional sites are needed.
    • Regulatory review takes 45 days for standard applications, shortening to 15-30 days through expedited pathways.
    • Ethics committee reviews and site selection are generally completed within 8-12 weeks.
    • If the c-IRB mechanism operates sequentially, the main IRB review will take about 4 weeks, followed by sub-IRB reviews taking about 2 weeks.

     

    Site selection and investigator qualifications are carefully regulated to ensure high-quality trial execution. Clinical trials must be conducted at accredited facilities at or above the teaching hospital level, or at hospitals with relevant specialized expertise. Investigators must possess:

    • A valid practicing license
    • Minimum 5 years of clinical medicine experience
    • 30 hours of human clinical trial training
    • 9 hours of medical ethics education within a 6-year period

     

    Hong Kong Overview

     

    Hong Kong’s population consists of approximately 7.5 million people as of 2024, offering a substantial and diverse patient pool for medical research.

    Leading causes of death in Hong Kong include​ [3]:

    • Malignant neoplasms​
    • Pneumonia​
    • Heart disease​
    • Cerebrovascular diseases​
    • Nephritis, nephrotic syndrome, and nephrosis ​

     

    The region’s healthcare system is built on a universal framework. The Health Authority (HA) provides comprehensive medical services to citizens across a wide range of diseases and conditions. Notably, the system includes provisions for patients facing financial difficulties, allowing them to apply for medical fee assistance, which promotes broad patient participation in clinical trials.

    The HA also manages an extensive network of healthcare facilities strategically distributed throughout the region. This includes:

    • 40+ public hospitals and institutions​
    • 45+ Specialist out-patient clinics ​
    • 70+ General out-patient clinics ​

     

    Running Clinical Trials in Hong Kong

     

    The data generated from clinical trials in Hong Kong is globally recognized. One significant advantage is the absence of restrictions on importing and exporting biological specimens, which streamlines the research process and facilitates international collaboration.

    The region is set to introduce two significant improvements to its clinical trial framework:

    1. An improved ethics review process for multi-center studies will streamline approvals across different research sites.
    2. The implementation of a standardized Clinical Trial Application (CTA) management system with a single point of contact will simplify the administrative aspects of conducting trials.

     

    Clinical trials in Hong Kong span a diverse range of therapeutic areas. The distribution of trials shows a clear focus on three primary therapeutic areas [3]:

    • Oncology
    • Infectious diseases
    • Endocrinology

     

    Hong Kong’s Fast Patient Targeting

     

    Hong Kong’s healthcare system utilizes eHealth, an electronic health record-sharing system developed by the Hong Kong government.

    This platform creates and maintains lifelong electronic health records for all members of the public. All eligible individuals and healthcare providers with valid supporting documents can join eHealth. Healthcare professionals with a valid professional registration status can apply to create an eHealth account under the healthcare provider they are working for.

    The eHealth system enables physicians to quickly identify and enroll subjects who meet protocol requirements, significantly reducing screening failures and dropout rates during clinical trials.

    There are currently 11 types of shareable data, including personal identification and demographic data, allergies and adverse drug reactions, diagnosis, procedures and medication, clinical notes/summaries, birth and immunization records, and healthcare referrals [4].

    During feasibility periods, the system supports the gathering of accurate data and the making of informed decisions. When sites face limited patient pools, the platform facilitates quick patient referrals, increasing the efficiency of trial recruitment and execution.

    Leveraging investigations of targeted populations in clinical trials provides several key advantages :

    • See a more detailed record of potential patients and obtain the feasibility and site selection results as accurately as possible from the site, enabling quick and informed decision-making.​
    • By accessing data on patient medical visits through eHealth, sites can identify and enroll subjects who best meet protocol requirements, reducing screening failures and dropout rates.
    • In cases where sites have limited patient resources, the platform facilitates efficient referrals, enhancing recruitment outcomes and overall trial success.

     

    Hong Kong’s Regulatory Environment

     

    Hong Kong’s regulatory framework for clinical trials allows for parallel submissions to both the Department of Health (DOH) and the Ethics Committee (EC), though final DOH approval can only be issued after receiving EC approval. The submission process has been streamlined to align with international standards, requiring common protocol documentation while maintaining specific local requirements.

    The submission package must include standard elements such as protocols and investigational product information.

    For CMC documentation, only certificates of analysis and GMP evidence are required. Translation requirements are limited to informed consent forms and subject materials, which must be provided in traditional Chinese or as bilingual documents in Chinese and English. Online submission is mandatory for clinical trial applications and import license applications, with a submission fee of approximately 400 USD.

    The 1+ mechanism, recently introduced in Hong Kong, offers an expedited pathway for market authorization. This scheme is specifically designed for treatments targeting life-threatening or severe diseases. To qualify, companies must have obtained Orphan Drug Designation, Breakthrough Therapy Designation, or similar recognition from one of the reference countries, and the product must already be approved and marketed in those countries. The scheme requires additional documentation, including an assessment report from a qualified academician with over 5 years of experience in the relevant medical field, along with comprehensive safety summary reports.

    Timelines from start to Clinical Trial Certificate (CTC):

    • Total process: approximately 6 months
    • EC review: 6-12 weeks
    • Contract negotiations: 12-18 weeks
    • Import license: 1 week (after CTC issuance)

     

     

    HiRO’s Experience and Support

     

    HiRO recently supported a CAR-T therapy project in Taiwan, overseeing the entire trial process from regulatory submission to monitoring services. Our team successfully coordinated complex international logistics, including specimen shipping between the US and Taiwan,  while ensuring compliance with regulatory requirements, including GTP on-site inspections. The entire process was completed efficiently within a 4-month timeframe.

    With extensive experience and expert teams across multiple regions in APAC, Europe, and the US, HiRO’s expertise spans a wide range of therapeutic areas, making us a trusted partner for clinical trial success worldwide.

     

     

    References:

    [1] https://www.taiwanclinicaltrials.tw/tw

    [2] https://www.taiwanclinicaltrials.tw/tw/spotlight/health_overview/nation_health

    [3] CITELINE

    [4]  https://www.ehealth.gov.hk/en/whats-ehealth/index.html

    • Previous PostMaximizing Global Study Value: Clinical Trial Landscapes in South Korea and Japan

    • Next PostNavigating Clinical Trials in the Philippines and Malaysia: Insights and Opportunities

    Related Posts

    HiRO-Topic-of-the-Moment-Obesity-and-Weight-Loss-GLP-1 Blogs Obesity vs. Weight Management Trials: What changes when the goal shifts from losing weight to keeping it off?

    Obesity vs. Weight Management Trials: What changes when the goal shifts from losing weight to keeping it off?

    Obesity vs. Weight Management Trials: Two Studies, Two Questions Obesity and weight management trials often…
    harvestiro
    harvestiroNovember 2, 2026
    Blogs Where Human Expertise Still Wins: AI, Automation, and the Future of Clinical Research

    Where Human Expertise Still Wins: AI, Automation, and the Future of Clinical Research

    Part 5 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
    harvestiro
    harvestiroOctober 21, 2026
    Blogs Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials

    Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials

    Part 4 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
    harvestiro
    harvestiroSeptember 11, 2026

    HiRO brings the strength of a global organization together with the agility and insight of regional teams. By linking people, systems, and expertise across continents, we give sponsors a Modern CRO experience — one that adapts to regional challenges while maintaining disciplined, transparent execution everywhere we operate.

    North America

    220 Davidson Ave.
    Ste. 201
    Somerset, NJ 08873

    202 Water Street
    Ste. 201
    Excelsior, MN 55331

    Em. info@harvestiro.com

    Europe

    Asia Pacific

    Australia / New Zealand

    Links

    Clinical Data Science

    Regulatory Affairs

    Clinical Operations

    Medical Writing

    Medical Monitoring

    Pharmacovigilance

    Oncology

    Quality Assurance

    About Us

    Sign Up For Industry
    News and More

      © 2026 All Rights Reserved HiRO

      Privacy Statement

      Share
      Share Share Share Pin
      Close Menu
      • About Us
      • Service Modes
        • Functional Service Provider
        • Clinical Data Science
        • Clinical Operations
        • Medical Monitoring
        • Pharmacovigilance
        • Quality Assurance
        • Regulatory Affairs
        • Medical Writing
      • Therapeutic Expertise
        • Oncology
        • Rare Diseases
        • Healthy Volunteers
        • Dermatology
        • Metabolic
      • Modalities
        • Radiopharmaceutical
        • Cell and Gene Therapy
      • Regions
        • U.S.
        • APAC
        • ANZ
        • Europe
      • Updates
        • Events and News
        • Blogs
        • Case Studies
        • View All
      • Contact
      • Start Your RFP